, /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: ), today announced that , Ph.D.
, will retire as Chief Executive Officer of Neurocrine on . , Ph.D.
, currently Neurocrine's Chief Business Development and Strategy Officer, will succeed him in the CEO role. Dr. Gano will also join the Company's Board of Directors at that time, and Dr.
Gorman will continue to serve on the Neurocrine Board. Dr. Gorman founded Neurocrine in 1992 and held numerous positions across the Company, including Chief Operating Officer, Chief Business Officer, and Senior Vice President of Business Development, before being appointed CEO in 2008.
Under Dr. Gorman's three decades of leadership, Neurocrine has emerged as a fully integrated biopharmaceutical enterprise with a broad, mature pipeline, strong financial position, and highly successful commercial product, INGREZZA® (valbenazine). Dr.
Gorman's vision to focus on areas that lack recent innovation or have limited treatment options has provided the Company with meaningful momentum in its mission to discover and develop new medicines that relieve patient suffering. Notably, in late April, Neurocrine submitted to the FDA two New Drug Applications for crinecerfont as a treatment for adult and pediatric patients with classic congenital adrenal hyperplasia (CAH). In addition, the Company now has 17 clinical development programs in its pipeline focusing on helping patients across neurology, neuroendocrinology, and neuropsychology.
With a growing multi-.
